- Patent Title: Highly potent TACC3 inhibitor as a novel anticancer drug candidate
-
Application No.: US17058982Application Date: 2019-03-14
-
Publication No.: US11622966B2Publication Date: 2023-04-11
- Inventor: Erden Banoglu , Burcu Caliskan , Ozgur Sahin , Deniz Lengerli , Ozge Akbulut
- Applicant: A2A Pharmaceuticals, Inc. , OncoCube Therapeutics LLC
- Applicant Address: US NY New York; US DE Wilmington
- Assignee: A2A Pharmaceuticals, Inc.,OncoCube Therapeutics LLC
- Current Assignee: A2A Pharmaceuticals, Inc.,OncoCube Therapeutics LLC
- Current Assignee Address: US NY New York; US DE Wilmington
- Agency: Foley Hoag LLP
- Agent Lucas P. Watkins; Alexander J. Chatterley
- Priority: TR2018/07464 20180525
- International Application: PCT/TR2019/050164 WO 20190314
- International Announcement: WO2020/018039 WO 20200123
- Main IPC: A61K31/5377
- IPC: A61K31/5377 ; A61P35/00
Abstract:
The present invention relates to a new inhibitor chemotype 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine (BO-264) targeting TACC3 protein with high potency as a mitotic blocker for the treatment of breast and potentially other cancers.
Public/Granted literature
- US20210220369A1 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE Public/Granted day:2021-07-22
Information query
IPC分类:
